Dr. Navada is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 E 102nd St
New York, NY 10029Phone+1 212-241-6756Fax+1 212-348-9233
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2007 - 2010
University of MichiganResidency, Internal Medicine, 2004 - 2007
University of Illinois College of MedicineClass of 2004
Certifications & Licensure
NY State Medical License 2007 - 2025
MI State Medical License 2004 - 2007- American Board of Internal Medicine Hematology
Clinical Trials
- Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropo...Mikkael A Sekeres, Valeria Santini, Maria Díez-Campelo, Rami S Komrokji, Pierre Fenaux
Leukemia & Lymphoma. 2024-11-13 - CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) ...Yazan Madanat, Michael R Savona, Mikkael A Sekeres, Uwe Platzbecker, Valeria Santini
Journal of the National Comprehensive Cancer Network. 2024-04-05 - HSR24-159: Relationship Between Durable Transfusion Independence (TI) and Survival Outcomes in Patients (Pts) With Lower-Risk Myelodysplastic Syndrome (LR-MDS): An Ana...Rami S Komrokji, Nishan Sengupta, Dylan Supina, Shyamala Navada, Ravi Potluri
Journal of the National Comprehensive Cancer Network. 2024-04-05
Abstracts/Posters
- Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidin...Shyamala C. Navada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/_-Catenin Signaling and Downstream Hematopoi...Shyamala C. Navada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous ImmunoglobulinShyamala C. Navada, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual MeetingDecember 5th, 2016
Other Languages
- French, Kannada
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
